Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sudeep PharmaBOM:544619 -1.10%18 Return-on-Tangible-Equity is 24.19% as of Mar. 2026, which is 20% below its 10-year median of 30.33. GuruFocus rates BOM:544619 with a GF Score™ of 18/100. The stock has 5 warning signs investors should review. Among 901 Drug Manufacturers companies, Sudeep Pharma ranks better than 78.69% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Sudeep Pharma's annualized net income for the quarter that ended in Mar. 2026 was ₹1,955 Mil. Sudeep Pharma's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹8,083 Mil. Therefore, Sudeep Pharma's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 24.19%.
The historical rank and industry rank for Sudeep Pharma's Return-on-Tangible-Equity or its related term are showing as below:
BOM:544619'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 19.93 Med: 30.33 Max: 46.04
Current: 19.93
During the past 4 years, Sudeep Pharma's highest Return-on-Tangible-Equity was 46.04%. The lowest was 19.93%. And the median was 30.33%.
BOM:544619's Return-on-Tangible-Equity is ranked better than 78.69% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.87
vs BOM:544619: 19.93
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Sudeep Pharma Return-on-Tangible-Equity Related Terms
Sudeep Pharma Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Sudeep Pharma's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544619 vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sudeep Pharma's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sudeep Pharma Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sudeep Pharma's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Sudeep Pharma's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 24.19% mean?
Sudeep Pharma (BOM:544619) has a Return-on-Tangible-Equity of 24.19% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sudeep Pharma and its competitors. This is 20% below median its historical median of 30.33. Over the past decade, Sudeep Pharma's Return-on-Tangible-Equity has ranged from 19.93 to 46.04. According to the industry distribution chart, Sudeep Pharma ranks #192 out of 901 companies in the Drug Manufacturers industry, placing it in the top 21.3%.
Is Sudeep Pharma's Return-on-Tangible-Equity too high?
Sudeep Pharma's current Return-on-Tangible-Equity of 24.19% is 20% below median its 10-year median of 30.33. Over the past 10 years, this metric has ranged from a low of 19.93 to a high of 46.04. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.87. Sudeep Pharma's value of 24.19% is 207.4% above this industry median. Based on the distribution chart, Sudeep Pharma ranks #192 out of 901 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sudeep Pharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sudeep Pharma's Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sudeep Pharma ranks #192 out of 901 companies for Return-on-Tangible-Equity. This places Sudeep Pharma in the top 21% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.87. Sudeep Pharma's value of 24.19% is 207.4% above this benchmark. Historically, Sudeep Pharma's own Return-on-Tangible-Equity has ranged from 19.93 to 46.04 over the past decade. While the company's 10-year median is 30.33 vs. the industry median of 7.87, Sudeep Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.87, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sudeep Pharma's current Return-on-Tangible-Equity of 24.19% is 207.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sudeep Pharma and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sudeep Pharma's current Return-on-Tangible-Equity is 24.19%, which is 20% below median its own 10-year median of 30.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sudeep Pharma stock overvalued right now?
Sudeep Pharma (BOM:544619) has a current Return-on-Tangible-Equity of 24.19%. The current Return-on-Tangible-Equity is 24.19%, which is 20% below median its 10-year median of 30.33 and 207.4% above the Drug Manufacturers industry median of 7.87. Sudeep Pharma's overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Sudeep Pharma (BOM:544619), the current Return-on-Tangible-Equity is 24.19% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sudeep Pharma Ltd is a technology led manufacturer of excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries and is dedicated to contributing to the healthcare ecosystem. The company operates in two business verticals: Pharmaceutical, food, and nutrition. It focuses on providing refined, mineral-based single ingredients essential to the pharmaceutical, food, and nutrition industries and Specialty ingredients: It pertains manufacturing of specialty ingredients using advance technology solutions. The maximum revenue is generated from the Pharmaceutical, food, and nutrition segment. Geographically, it has presence in the United States, South America, Europe, the Middle East, Africa, and Asia-Pacific.
18GF Score
Get the complete analysis for BOM:544619
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544619 has been successfully added to your 
